Abstract:Voltage-gated Kv7/KCNQ/M potassium channels play an essential role in the control of membrane potential and neuronal excitability. Activation of the neuronal Kv7/KCNQ/M-current represents an attractive therapeutic strategy for treatment of hyperexcitability-related neuropsychiatric disorders such as epilepsy, pain, and depression, which is an unmet medical need. In this study, we synthesized and characterized a novel compound, N-(4-(2-bromo-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide (SCR2682) 2,6-dimethyl-4-(piperidin-yl) phenyl)-amide derivative, that exhibits selective and potent activation of neuronal Kv7/KCNQ/M-channels. Whole-cell patch-clamp recordings of human embryonic kidney 293 cells expressing Kv7.2/Kv7.3 channels show that SCR2682 selectively activates the channel current in a dose-dependent manner with an EC50 of 9.8 +/- 0.4 nM, which is similar to 100-fold more potent than a U.S. Food and Drug Administration-approved antiepileptic drug (retigabine) for treatment of partial epilepsy. SCR2682 shifts voltage-dependent activation of the Kv7.2/7.3 current toward more negative membrane potential, to about -37 mV (V-1/2). SCR2682 also activates the native M-current in rat hippocampal or cortical neurons, causing marked hyperpolarization and potent inhibition of neuronal firings. Mechanistically, mutating the tryptophan residue 236 located at the fifth transmembrane segment of Kv7.2 abolishes the chemical activation of the channel by SCR2682. Furthermore, intraperitoneal or intragastric administration of SCR2682 results in a dose-dependent inhibition of seizures by maximal electroshock. Taken together, our findings demonstrate that a novel small molecule, SCR2682, selectively and potently activates neuronal Kv7 channels and reverses epileptic seizures in rodents. Thus, SCR2682 may warrant further evaluation for clinical development of antiepileptic therapy.-Zhang, F., Liu, Y., Tang, F., Liang, B., Chen, H., Zhang, H., Wang, K. Electrophysiological and pharmacological characterization of a novel and potent neuronal Kv7 channel opener SCR2682 for antiepilepsy.

Isoform-specific Prolongation of Kv7 (KCNQ) Potassium Channel Opening Mediated by New Molecular Determinants for Drug-Channel Interactions

Structural Basis for the Modulation of Human KCNQ4 by Small-Molecule Drugs

Molecular Basis for Ligand Activation of the Human KCNQ2 Channel.

Discovery of Potent and Selective Blockers Targeting the Epilepsy-Associated KNa1.1 Channel.

Four drug-sensitive subunits are required for maximal effect of a voltage sensor–targeted KCNQ opener

Functional characterization and in vitro pharmacological rescue of KCNQ2 pore mutations associated with epileptic encephalopathy

Identification of a New Retigabine Derivative with Improved Photostability for Selective Activation of Neuronal Kv7 Channels and Antiseizure Activity.

Pharmacological Activation of Neuronal Voltage-Gated Kv7/KCNQ/M-Channels for Potential Therapy of Epilepsy and Pain.

Pore- and voltage sensor–targeted KCNQ openers have distinct state-dependent actions

A Small-Molecule Activation Mechanism That Directly Opens the KCNQ2 Channel

Discovery of Potent and Selective Blockers Targeting the Epilepsy-Associated K Na 1.1 Channel

Molecular determinants of KCNQ1 channel block by a benzodiazepine.

Multifaceted Regulation of Potassium-Ion Channels by Graphene Quantum Dots.

Design, Synthesis and Biological Activity of Pyrazolo[1,5-A]pyrimidin-7(4h)-ones As Novel Kv7/KCNQ Potassium Channel Activators

Electrophysiological and Pharmacological Characterization of a Novel and Potent Neuronal Kv7 Opener SCR2682 for Anti-Epilepsy

Pharmacological Activation of Normal and Arrhythmia-Associated Mutant KCNQ1 Potassium Channels

Retigabine and gabapentin restore channel function and neuronal firing in a cellular model of an epilepsy-associated dominant-negative KCNQ5 variant

The Gating Charge Pathway of an Epilepsy-Associated Potassium Channel Accommodates Chemical Ligands

Functional Analysis of Potassium Channels in Kv7.2 G271V Mutant Causing Early Onset Familial Epilepsy

A Kv2 inhibitor combination reveals native neuronal conductances consistent with Kv2/KvS heteromers

A new twist to increase ion flow